February 10, 2026/
New Zealand's Medsafe provides clear guidelines outlining the responsibilities and processes for ensuring participant safety during clinical investigations of both medicines and medical devices.
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
New Zealand's Medsafe provides clear guidelines outlining the responsibilities and processes for ensuring participant safety during clinical investigations of both medicines and medical devices.
The signals include a new safety concern for Kounis syndrome with cefazolin and epiphysiolysis with erdafitinib and a rare renal adverse event with pegylated liposomal doxorubicin....
This is the 19th volume, 12th issue of the EPVC’s monthly newsletter, published in December 2025. It serves as an official communication from the Egyptian Drug Authority (EDA) to healthcare professionals,...
